191 related articles for article (PubMed ID: 17532762)
1. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
[No Abstract] [Full Text] [Related]
2. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Bibb J; Hromas R; Rabinowitz I
J Clin Oncol; 2005 Dec; 23(34):8911-3. PubMed ID: 16314654
[No Abstract] [Full Text] [Related]
4. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.
Tempescul A; Querellou S; Ianotto JC; Boisramé S; Valette G; Berthou C
Ann Hematol; 2010 Jun; 89(6):635-7. PubMed ID: 19844711
[No Abstract] [Full Text] [Related]
6. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.
Han HS; Escalón MP; Hsiao B; Serafini A; Lossos IS
Ann Oncol; 2009 Feb; 20(2):309-18. PubMed ID: 18842613
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
[No Abstract] [Full Text] [Related]
9. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
[No Abstract] [Full Text] [Related]
10. [An update on recent developments in non-Hodgkin's lymphoma].
Bouabdallah K; Milpied N
Bull Cancer; 2007 Jan; 94(1):43-52. PubMed ID: 17237004
[TBL] [Abstract][Full Text] [Related]
11. Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report.
Pirozzi A; Cartenì G; Scagliarini S; Fusco M; Riccardi F
Medicine (Baltimore); 2019 Mar; 98(11):e14805. PubMed ID: 30882658
[TBL] [Abstract][Full Text] [Related]
12. [Primary non-Hodgkin's lymphoma of the prostate].
Swierz J; Zieliński H; Dabek A
Pol Merkur Lekarski; 1996 Oct; 1(4):278-9. PubMed ID: 9156946
[TBL] [Abstract][Full Text] [Related]
13. False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Ford CD; Gabor F; Morgan R; Dabbas B
Clin Nucl Med; 2006 Jul; 31(7):391-3. PubMed ID: 16785805
[TBL] [Abstract][Full Text] [Related]
14. [Follicular lymphoma showing long-term false positive results by FDG-PET after rituximab-containing chemotherapy].
Miyazaki Y; Nawa Y; Kohashi S; Nakase K; Miyagawa M; Hara M
Rinsho Ketsueki; 2012 Feb; 53(2):252-4. PubMed ID: 22450588
[TBL] [Abstract][Full Text] [Related]
15. A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.
Komoto D; Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Toyama Y; Satoh K; Ohno M; Kanenishi K; Ohkawa M
Ann Nucl Med; 2006 Feb; 20(2):157-60. PubMed ID: 16615426
[TBL] [Abstract][Full Text] [Related]
16. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report.
Ustaalioglu BB; Bilici A; Seker M; Canpolat N; Ozdemir N; Salepci T; Gumus M
Leuk Res; 2010 Apr; 34(4):e108-10. PubMed ID: 19931906
[No Abstract] [Full Text] [Related]
17. 18F-FDG-PET/CT in lymphoma: two decades of experience.
Alvarez Páez AM; Nogueiras Alonso JM; Serena Puig A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):340-9. PubMed ID: 22841459
[TBL] [Abstract][Full Text] [Related]
18. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Hanna F; Prakash A; Allan E; Khalafallah AA
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29549134
[TBL] [Abstract][Full Text] [Related]
20. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
